Aspire Biopharma Holdings, Inc. (ASBP) scores 43 out of 100 on boothcheck's 11-model valuation framework. Verdict: Avoid The estimated fair value is 0.01, representing a 99% premium to fair value. Quantitative score: 43/100. Qualitative score: 70/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.